Australia Cancer Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Country Level
  • 350 Pages
  • No of Tables: 97
  • No of Figures: 30

Australia Cancer Treatment Market, By Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics), Country (Australia) - Industry Trends and Forecast  to 2029

Market Analysis and Insights : Australia Cancer Treatment Market

The Australia cancer treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 14.0% in the forecast period of 2022 to 2029 and is expected to reach USD 4,243.39 million by 2029 from USD 1,697.91 million in 2021. The high prevalence of cancer and increasing R&D activities for its effective application are likely to be the major drivers that propel the market's demand in the forecast period.

Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor. This process is called metastases. The cancerous tumor is also referred to as a malignant tumor. The benign tumor does not invade nearby tissues, and when removed, benign tumors usually don't grow back, whereas cancerous tumors sometimes do.

There are more than a hundred types of cancer. Some categories of cancers that begin in specific types of cells include carcinoma, sarcoma, leukemia, lymphoma, and multiple myeloma, among others. Many types of cancer are available based on the type of cancer treatments. Cancer treatment includes biomarker testing, chemotherapy, hormone therapy, hyperthermia, immunotherapy, photodynamic therapy, radiation therapy, surgery, stem cell transplant, and targeted therapies.

According to GLOBOCAN, 19,292,789 new cancer cases were found in 2020 worldwide. The highest cases of breast cancer were found. Therefore, the high prevalence of cancer, initiatives taken by the government for awareness and early detection of cancer, and ongoing clinical trials are expected to fuel the market's growth. The high prevalence of cancer in Canada is expected to act as a driver for the growth of the market. However, the lack of an early diagnosis may restrain the market growth. The rise in government initiatives for early detection of cancer is expected to act as an opportunity for the growth of the market. However, the side effects of drugs may challenge the market's growth.

The Australia cancer treatment market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Australia Cancer Treatment Market

Australia Cancer Treatment Market Scope and Market Size

The Australia cancer treatment market is categorized into four notable segments based on cancer type, treatment, route of administration, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of cancer type, the Australia cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma. In 2022, the breast cancer segment is expected to dominate the market because of the high prevalence of breast cancer.
  • On the basis of treatment, the Australia cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others. In 2022, the medication segment is expected to dominate the market because of increasing approvals of cancer drugs in the region.
  • On the basis of route of administration, the Australia cancer treatment market is segmented into injectable, oral, and others. In 2022, the injectable segment is expected to dominate the market because of the launch of cancer drugs in injectable form.
  • On the basis of end user, the Australia cancer treatment market is segmented into hospitals and specialty clinics. In 2022, the hospitals segment is expected to dominate the market as the big hospitals are offering advanced cancer treatment.

Australia Cancer Treatment Market Country Level Analysis

The Australia cancer treatment market is analyzed, and market size information is provided by country, cancer type, treatment, route of administration, and end user.

Australia is expected to grow due to the presence of prominent market players in the region. The players are launching advanced cancer treatment medications for the patients.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Australian brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the Australia Cancer Treatment Market

The Australia cancer treatment market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the dental instruments market. The data is available for the historical period 2011 to 2020.

Competitive Landscape and Australia Cancer Treatment Market Share Analysis

The Australia cancer treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the Australia cancer treatment market.

Some of the major companies in the Australia cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for cancer treatment are bridging the gap for various treatments.

For instance,

  • In January 2020, Novartis AG declared the acquisition with the Medicines Company. This acquisition has provided a novel opportunity to escalate its geographical presence worldwide. As well as it has helped in upgrading the product portfolio of the company

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the cancer treatment market, which also benefits the organization to improve their offering for the Australia cancer treatment market.

Customization Available: Australia Cancer Treatment Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report. 


SKU-

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 40 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 AUSTRALIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 AUSTRALIA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 55 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 AUSTRALIA INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 57 AUSTRALIA ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 58 AUSTRALIA OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 59 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 AUSTRALIA HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 61 AUSTRALIA SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 62 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 63 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 64 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 65 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 AUSTRALIA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 90 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 91 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 92 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 93 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 94 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 97 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions